4D Molecular Therapeutics, Inc.FDMTEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| NOS. OF ABOVE PERSONS | 11.00% | 5.1M | ▲ +1.01pp | 2024-11-15 |
| BlackRock, Inc. | 10.70% | 5.0M | ▲ +1.30pp | 2024-12-06 |
| NOS. OF ABOVE | 9.70% | 4.2M | — | 2024-02-14 |
| Venrock Healthcare Capital Partners III, L.P. | 8.90% | 4.4M | — | 2024-02-14 |
| Deep Track Capital, LP | 7.88% | 4.1M | ▲ +2.54pp | 2024-11-14 |
| Biotechnology Value Fund, L.P. | 7.50% | 3.9M | ▲ +2.50pp | 2024-11-13 |
| THE GOLDMAN SACHS GROUP, INC. | 6.90% | 3.6M | — | 2024-11-06 |
| S.S. OR | 6.00% | 3.1M | ▼ -1.20pp | 2024-11-14 |
| The Vanguard Group | 5.32% | 2.8M | flat | 2024-11-12 |
| David Kirn | 4.70% | 2.0M | — | 2024-02-14 |
| Viking Global Investors LP | 0.00% | 35.1K | ▼ -9.90pp | 2024-11-14 |
Insider Transactions
Net 90d: −$3.4K · buys $0 / sells $3.4KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-20 | Ashoo Gupta | VP, Finance and Controller | Option exercise | 865 | — | — |
| 2026-03-20 | Ashoo Gupta | VP, Finance and Controller | Sell (open market) | 310 | $8.61 | $2.7K |
| 2026-03-20 | Ashoo Gupta | VP, Finance and Controller | Option exercise | 221 | — | — |
| 2026-03-20 | Ashoo Gupta | VP, Finance and Controller | Sell (open market) | 80 | $8.61 | $689 |
1–4 of 4